Clinical Trial Imaging Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

The Clinical Trial Imaging Market is segmented by Product and Service (Trial Design Consulting Services, Read Analysis Services, Operational Imaging Services, and Imaging Software), Modality (Magnetic Resonance Imaging, Computed Tomography, Ultrasound, Positron Emission Tomography, X-Ray, Echocardiography, and Other Modalities), End User (Pharmaceutical Companies, Medical Device Manufacturers, and Academic and Government Research Institutes), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Clinical Trial Imaging Industry Overview

Clinical Trial Imaging Market Summary
Study Period: 2019-2027
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 6.5 %

Major Players

Clinical Trial Imaging Market Major Players

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Clinical Trial Imaging Market Analysis

The Clinical Trial Imaging Market is projected to register a CAGR of 6.5% during the forecast period.

Clinical trials are used in the development and testing of vaccines and other therapeutics; they have been essential in containing the COVID-19 pandemic. For instance, using low-field magnetic resonance imaging, the University of Erlangen-Nürnberg Medical School started a clinical study in August 2021 to assess the prevalence of pulmonary skeletal changes in children and adolescents with verified past SARS-CoV-2 infection (LF-MRI).

Increasing research and development by the key market players during the pandemic is expected to increase market growth during the forecast period. For instance, in August 2021, the government of Canada announced an agreement with leading COVID­-19 vaccine developer Moderna, Inc. to build an mRNA vaccine facility in Canada. The goals of the recently unveiled biomanufacturing and life science strategy were in line with Moderna's aspirations to build an mRNA vaccine manufacturing facility in Canada. This is anticipated to drive the clinical trial imaging market growth in Canada, driving the overall growth of the market.

The clinical trial imaging market is expected to grow also due to the rise in the number of contract research organizations, an increase in R&D spending, and growth in pharmaceutical and biotechnological companies. In recent years, various pharmaceutical companies and government organizations have increased their spending on research and development (R&D), which is anticipated to drive the market growth over the forecast period. For example, in FY 2021 Novartis AG, one of the leading participants in the studied market, invested USD 14,886 million, up from USD 14,197 million in the previous year, according to annual reports. Such large investments will provide an impetus to market growth.

Additionally, the market is expected to grow as a result of increased investment in research and development in the biopharmaceutical industry. For instance, the annual research and development expenditure of the biopharmaceutical industry has been 7.3 times greater than that of the aerospace and defense industries, 6.5 times greater than that of the chemicals industry, and 1.5 times greater than that of the software and computer services industry, as per our analysis. Further, as per the IFPMA, in 2022, over 202 billion is estimated to have been spent around the world in biopharmaceutical research and development. The enormous investments in the market are considered a result of the rising acceptance of biopharmaceuticals over the years.

Similarly, increasing contract research organizations are expected to increase the market growth. For instance, in September 2021, Insights Research Organization and Solutions (IROS) – a Contract Research Organization (CRO) in the UAE was launched, specializing in healthcare research and solutions to cover all therapeutic areas.

However, high implementation barriers and costs of imaging systems are expected to hinder market growth.

Clinical Trial Imaging Industry Segments

Clinical trial imaging is an important part of the research and development process in the pharmaceutical and biotechnology industries. The usage of medical imaging is now recognized in clinical trials to make trials more effective and accurate. The Clinical Trial Imaging Market is segmented by Product and Service (Trial Design Consulting Services, Read Analysis Services, Operational Imaging Services, and Imaging Software), Modality (Magnetic Resonance Imaging, Computed Tomography, Ultrasound, Positron Emission Tomography, X-Ray, Echocardiography, and Other Modalities), End User (Pharmaceutical Companies, Medical Device Manufacturers, and Academic and Government Research Institutes), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Product and Service
Trial Design Consulting Services
Read Analysis Services
Operational Imaging Services
Imaging Software
By Modality
Magnetic Resonance Imaging
Computed Tomography
Ultrasound
Positron Emission Tomography
X-Ray
Echocardiography
Other Modalities
By End-User
Pharmaceutical & Biotechnology Companies
Medical Device Manufacturers
Academic and Government Research Institutes
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Clinical Trial Imaging Market Trends

This section covers the major market trends shaping the Clinical Trial Imaging Market according to our research experts:

Computed Tomography is Expected to Witness Rapid Growth Over the Forecast Period

Computed tomography is a non-invasive medical procedure that uses X-rays to generate cross-sectional images of the body and provides detailed information for treatment while examining abnormalities in children and adults. Factors such as increasing clinical trials and initiatives by the key players are expected to increase market growth.

There are currently 410,319 registered studies, including 61,961 recruiting studies and 169,924 pharmaceutical or biologic studies, dispersed over all 50 states in the US and 220 countries worldwide, according to Clinicaltrials.gov's April 7, 2022, updated figures. As a result, when various types of pharmaceuticals are being created, there will likely be a high need for clinical trial imaging services. Product approval is another factor in market growth. For instance, the Siemens NAEOTOM Alpha device represented a significant technological advance in computed tomography imaging when it received approval from the United States Food and Drug Administration in September 2021. It employs detectors to measure the overall energy present in several x-rays simultaneously. NAEOTOM Alpha measures each x-ray that travels through a patient's body using the cutting-edge CT technology of photon-counting detectors. While minimizing information that is not necessary for the review and analysis, more precise information about the patient can be acquired and used to build images.

Further, acquisitions are one of the key factors behind market expansion, as with acquisitions organizations develop and broaden the scope of the products and services they offer. For instance, MILabs B.V. was acquired by Rigaku Corporation in August 2021. By merging MILabs' multi-modality activities, which include PET, SPECT, optical imaging, and CT, Rigaku extended its life sciences modality business globally. Therefore, it is anticipated that during the predicted time, these acquisitions will contribute to the market's growth. 

Clinical Trial Imaging Market : Total Number of Registered Cancer Clinical Trials (in Number), By Region, Global

North America is Expected to Dominate the Market Over the Forecast Period

North America is expected to dominate the market during the forecast period. The increasing funding from the United States government for supporting healthcare will contribute to the market's growth in the region. For instance, a 2021 assessment from the Congressional Budget Office found that the National Institutes of Health (NIH) collected more than USD 700 billion in public financing over the previous three decades. Increasing funding is predicted to increase market growth by providing the essential infrastructure to expand clinical trials in the area, increasing the requirement for clinical trial imaging in the area throughout the forecast period. 

Additionally, according to Pfizer Inc.'s annual report for 2021, the company spent USD 13,829 million on R&D in FY 2021, up significantly from USD 9,393 in the previous year. It is predicted that more products in the company's portfolio will be eligible for clinical studies, which will fuel market expansion in the area. Key companies are expected to expand R&D, which will accelerate market expansion. As of October 2022, "clinicaltrials.gov" reported that 42,240 oncology clinical studies had been registered in the country. As a result, it is predicted that both public and private organizations will increase their spending on research and development over the forecast period.

Similarly, initiatives such as the Canadian government's grant approval to keep conducting cancer studies there are contributing causes to the market's expansion. For instance, the Canadian Cancer Society (CCS) promised the national research network in April 2022 a five-year, USD 30 million investment in support of the Canadian Cancer Trials Group (CCTG). When CCS contributed to the creation of the Canadian Academic Research Group in 1980, it made its largest commitment to research, which the grant extension continues. Such partnerships are anticipated to accelerate market expansion during the anticipated time frame. 

Clinical Trial Imaging Market- Growth Rate by Region

Clinical Trial Imaging Market Competitor Analysis

The Clinical Trial Imaging Market is moderately competitive and consists of several major players. The key participants of the market studied include Koninklijke Philips N.V, Ixico PLC, Icon PLC, WIRB-Copernicus Group, and Navitas Clinical Research, Inc among others. These major players are undertaking growth strategies such as new product launches, mergers, and acquisitions to retain shares and diversify their product portfolios.

Clinical Trial Imaging Market Top Players

  1. Koninklijke Philips N.V

  2. Icon PLC

  3. WIRB-Copernicus Group

  4. Ixico PLC

  5. Navitas Clinical Research, Inc

*Disclaimer: Major Players sorted in no particular order

Clinical Trial Imaging Market Concentration

Clinical Trial Imaging Market Recent Developments

  • In May 2022, at the International Society for Magnetic Resonance in Medicine (ISMRM) 2022 conference, Bruker launched innovative 7 Tesla and 9.4 Tesla conduction-cooled Maxwell magnets for its market-leading preclinical magnetic resonance imaging (MRI) systems portfolio.
  • In March 2022, Fujifilm India unveiled a new range of CT, MRI, and ultrasound machines in India. A wide range of equipment, including computed tomography (CT), magnetic resonance imaging (MR)I, X-ray, artificial intelligence, endoscopy, and ultrasound systems through the Scenaria View, Supria series, The Echelon Smart, and Arietta series, are included in the most recent portfolio.

Clinical Trial Imaging Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increase in R&D Spending by the Pharmaceutical and Biotechnological Companies

      2. 4.2.2 Increasing Number of Contract Research Organization & Investment by Them

    3. 4.3 Market Restraints

      1. 4.3.1 High Implementation Barriers and Costs of Imaging Systems

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value – USD million)

    1. 5.1 By Product and Service

      1. 5.1.1 Trial Design Consulting Services

      2. 5.1.2 Read Analysis Services

      3. 5.1.3 Operational Imaging Services

      4. 5.1.4 Imaging Software

    2. 5.2 By Modality

      1. 5.2.1 Magnetic Resonance Imaging

      2. 5.2.2 Computed Tomography

      3. 5.2.3 Ultrasound

      4. 5.2.4 Positron Emission Tomography

      5. 5.2.5 X-Ray

      6. 5.2.6 Echocardiography

      7. 5.2.7 Other Modalities

    3. 5.3 By End-User

      1. 5.3.1 Pharmaceutical & Biotechnology Companies

      2. 5.3.2 Medical Device Manufacturers

      3. 5.3.3 Academic and Government Research Institutes

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Clario

      2. 6.1.2 Icon PLC

      3. 6.1.3 Ixico PLC

      4. 6.1.4 Koninklijke Philips N.V

      5. 6.1.5 Medpace

      6. 6.1.6 Navitas Clinical Research, Inc

      7. 6.1.7 Parexel International Corporation

      8. 6.1.8 ProScan Imaging

      9. 6.1.9 Radiant Sage LLC

      10. 6.1.10 Resonance Health

      11. 6.1.11 WIRB-Copernicus Group

      12. 6.1.12 Worldcare Clinical LLC

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You can also purchase parts of this report. Do you want to check out a section wise price list?

Clinical Trial Imaging Market Research FAQs

The Clinical Trial Imaging Market market is studied from 2019 - 2027.

The Clinical Trial Imaging Market is growing at a CAGR of 6.5% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Koninklijke Philips N.V, Icon PLC, WIRB-Copernicus Group, Ixico PLC, Navitas Clinical Research, Inc are the major companies operating in Clinical Trial Imaging Market.

Clinical Trial Imaging Industry Reports

In-depth industry statistics and market share insights of the Clinical Trial Imaging sector for 2020, 2021, and 2022. The Clinical Trial Imaging research report provides a comprehensive outlook of the market size and an industry growth forecast for 2023 to (2023to28. Available to download is a free sample file of the Clinical Trial Imaging report PDF.

close-icon
80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!